Dr John Conibear graduated from the University Hospital of Wales in 2001 and completed his post-graduate general medical training in The Barts and The London Training rotation in 2006. Before gaining his substantive post as a consultant clinical oncologist in St. Bartholomew’s Hospital in 2014, he completed a 2-year fellowship with the NCRI Radiotherapy Trials Quality Assurance Group in Mount Vernon Hospital. During his fellowship he conducted research into techniques to improve clinician target outlining during radiotherapy planning and was subsequently awarded a MD(Res) from UCL in 2018. Dr Conibear is currently the stereotactic radiotherapy lead for HCA UK, the clinical director for thoracic and neuro-oncology in St. Bartholomew’s Hospital, and the oncology clinical lead for the National Lung Cancer Audit (NLCA). Dr Conibear was past Deputy Medical Director of Barts Cancer Centre and interim Divisional Director for clinical support services in Barts.
Additional specialties and sub-specialties
Clinical oncology
Special clinical interests
Dr Conibear specialises in all the non-surgical treatments for both lung and breast cancers and has a specialist interest in stereotactic radiosurgery (SRS). He has expertise in chemotherapy, biological therapy, immunotherapy, radiotherapy, and state of the art radiotherapy techniques. Dr Conibear is trained in using state of the art radiotherapy technologies and techniques including MR guided radiotherapy, Accuray Cyberknife, Leksell Icon GammaKnife, and Proton Therapy. These technologies are often used to deliver stereotactic ablative body or brain radiotherapy treatments (SABR / SRS).